Alex Adams

Alex Adams

Auto-generated profile, based on publicly available information

Alex Adams

Translational Gastroenterology Unit, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Gut
Verified
Journal Article
Closed access
PDF file
AAAlex Adams
Alex Adams
VGVipin Gupta
Vipin Gupta
WMWaled Mohsen
Waled Mohsen
TCThomas P. Chapman
Thomas P. Chapman
DSDeloshaan Subhaharan
Deloshaan Subhaharan
JSJack Satsangi
Jack Satsangi
Objectives We aimed to determine whether changes in acute severe colitis (ASC) management have translated to improved outcomes and to develop a simple model predicting steroid non-response on admission. Design Outcomes of 131 adult ASC admissions (117 patients) in Oxford, UK between 2015 and 2019 were compared with data from 1992 to 1993. All patients received standard treatment with intravenous corticosteroids and endoscopic disease activity scoring (Ulcerative Colitis Endoscopic Index of Severity (UCEIS)). Steroid non-response was defined as receiving medical rescue therapy or surgery. A predictive model developed in the Oxford cohort was validated in Australia and India (Gold Coast University Hospital 2015–2020, n=110; All India Institute of Medical Sciences, New Delhi 2018–2020, n=62). Results In the 2015–2019 Oxford cohort, 15% required colectomy during admission vs 29% in 1992–1993 (p=0.033), while 71 (54%) patients received medical rescue therapy (27% ciclosporin, 27% anti-tumour necrosis factor, compared with 27% ciclosporin in 1992–1993 (p=0.0015). Admission C reactive protein (CRP) (false discovery rate, p=0.00066), albumin (0.0066) and UCEIS scores (0.015) predicted steroid non-response. A four-point model was developed involving CRP of ≥100 mg/L (one point), albumin of ≤25 g/L (one point), and UCEIS score of ≥4 (1 point) or ≥7 (2 points). Patients scoring 0, 1, 2, 3 and 4 in the validation cohorts had steroid response rates of 100, 75.0%, 54.9%, 18.2% and 0%, respectively. Scoring of ≥3 was 84% (95% CI 0.70 to 0.98) predictive of steroid failure (OR 11.9, 95% CI 10.8 to 13.0). Colectomy rates in the validation cohorts were were 8%–11%. Conclusions Emergency colectomy rates for ASC have halved in 25 years to 8%–15% worldwide. Patients who will not respond to corticosteroids are readily identified on admission and may be prioritised for early intensification of therapy.

22 December 2023 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
YCYin-Huai Chen
Yin-Huai Chen
SZSarah van Zon
Sarah van Zon
AAAlex Adams
Alex Adams
Dirk Schmidt-ArrasDirk Schmidt-Arras
Dirk Schmidt-Arras
ALArian D. J. Laurence
Arian D. J. Laurence
HUHolm H. Uhlig
Holm H. Uhlig
Genetic variants in IL6ST encoding the shared cytokine receptor for the IL-6 cytokine family GP130 have been associated with a diverse number of clinical phenotypes and disorders. We provide a molecular classification for 59 reported rare IL6ST pathogenic or likely pathogenic variants and additional polymorphisms. Based on loss- or gain-of-function, cytokine selectivity, mono- and biallelic associations, and variable cellular mosaicism, we grade six classes of IL6ST variants and explore the potential for additional variants. We classify variants according to the American College of Medical Genetics and Genomics criteria. Loss-of-function variants with (i) biallelic complete loss of GP130 function that presents with extended Stüve-Wiedemann Syndrome; (ii) autosomal recessive hyper-IgE syndrome (HIES) caused by biallelic; and (iii) autosomal dominant HIES caused by monoallelic IL6ST variants both causing selective IL-6 and IL-11 cytokine loss-of-function defects; (iv) a biallelic cytokine-specific variant that exclusively impairs IL-11 signaling, associated with craniosynostosis and tooth abnormalities; (v) somatic monoallelic mosaic constitutively active gain-of-function variants in hepatocytes that present with inflammatory hepatocellular adenoma; and (vi) mosaic constitutively active gain-of-function variants in hematopoietic and non-hematopoietic cells that are associated with an immune dysregulation syndrome. In addition to Mendelian IL6ST coding variants, there are common non-coding cis-acting variants that modify gene expression, which are associated with an increased risk of complex immune-mediated disorders and trans-acting variants that affect GP130 protein function. Our taxonomy highlights IL6ST as a gene with particularly strong functional and phenotypic diversity due to the combinatorial biology of the IL-6 cytokine family and predicts additional genotype-phenotype associations.

12 February 2021 in Gut
Verified
Journal Article
Open access
PDF file
CMColleen GC McGregor
Colleen GC McGregor
AAAlex Adams
Alex Adams
RSRoss Sadler
Ross Sadler
CACarolina V Arancibia-Cárcamo
Carolina V Arancibia-Cárcamo
RPRebecca Palmer
Rebecca Palmer
JSJack Satsangi
Jack Satsangi

1 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
JNJan Nowak
Jan Nowak
CSCyntia Szymańska
Cyntia Szymańska
AGAleksandra Glapa-Nowak
Aleksandra Glapa-Nowak
RDRémi Duclaux-Loras
Rémi Duclaux-Loras
EDEmilia Dybska
Emilia Dybska
AAAlex T. Adams
Alex T. Adams
Although big data from transcriptomic analyses have helped transform our understanding of inflammatory bowel disease (IBD), they remain underexploited. We hypothesized that the application of machine learning using lasso regression to transcriptomic data from IBD patients and controls can help identify previously overlooked genes. Transcriptomic data provided by Ostrowski et al. (ENA PRJEB28822) were subjected to a two-stage process of feature selection to discriminate between IBD and controls. First, a principal component analysis was used for dimensionality reduction. Second, the least absolute shrinkage and selection operator (lasso) regression was employed to identify genes potentially involved in the pathobiology of IBD. The study included data from 294 participants: 100 with ulcerative colitis (48 adults and 52 children), 99 with Crohn’s disease (45 adults and 54 children), and 95 controls (46 adults and 49 children). IBD patients presented a wide range of disease severity. Lasso regression preceded by principal component analysis successfully selected interesting features in the IBD transcriptomic data and yielded 12 models. The models achieved high discriminatory value (range of the area under the receiver operating characteristic curve 0.61–0.95) and identified over 100 genes as potentially associated with IBD. PURA, GALNT14, and FCGR1A were the most consistently selected, highlighting the role of the cell cycle, glycosylation, and immunoglobulin binding. Several known IBD-related genes were among the results. The results included genes involved in the TGF-beta pathway, expressed in NK cells, and they were enriched in ontology terms related to immunity. Future IBD research should emphasize the TGF-beta pathway, immunoglobulins, NK cells, and the role of glycosylation.

29 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AYAndrew Li Yim
Andrew Li Yim
IHIshtu Hageman
Ishtu Hageman
VJVincent Joustra
Vincent Joustra
AEAhmed M.I.M. Elfiky
Ahmed M.I.M. Elfiky
Mohammed GhiboubMohammed Ghiboub
Mohammed Ghiboub
Peter HennemanPeter Henneman
Peter Henneman
Vedolizumab (VDZ) is a monoclonal antibody approved for the treatment of Crohn's disease (CD). Despite its efficacy, non-response to VDZ is common in clinical practice with no clear understanding of how it manifests. Here, we characterized the cellular repertoire of responders and non-responders to VDZ during treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from CD patients on VDZ treatment that were either steroid-free responder (N = 4) or non-responder (N = 4). Response was defined as ≥3 drop in Simple Endoscopic Score for Crohn's Disease (SES-CD) in combination with a ≥50% reduction in C-reactive protein (CRP) and fecal calprotectin and/or a ≥3 point drop in Harvey-Bradshaw Index (HBI). Single-cell repertoires were characterized using single-cell RNA-sequencing (scRNAseq) and mass cytometry by time of flight (CyTOF). Non-responders to VDZ presented more T cells, but fewer myeloid cells. T cells from non-responders presented lower expression of NFкB signaling inhibitors. A lower relative abundance of plasmacytoid dendritic cells (pDCs) was observed among non-responders. Moreover, non-responder-derived classical monocytes presented lower expression of genes involved in wound-healing and cytokine-cytokine receptor signaling. Taken together, non-response to VDZ during treatment is associated with differences in abundance and expression among T and myeloid cells.

19 December 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AAA. Adams
A. Adams
RKR. Kalla
R. Kalla
JSJ. Satsangi
J. Satsangi
Linked ContentThis article is linked to Lang et al papers. To view these articles visit https://doi.org/10.1111/apt.14378 and https://doi.org/10.1111/apt.14447.